HBM Healthcare Investments
 | |
| Company type | Public |
|---|---|
| HBMN.SW (SIX Swiss Exchange) | |
| Industry | Venture capital |
| Founded | 2001 |
| Founder | Henri B. Meier |
| Headquarters | |
Area served | Worldwide |
Key people | Hans Peter Hasler (Chairman) |
| AUM | $1.9B |
| Website | www.hbmhealthcare.com |
HBM Healthcare Investments is a publicly traded (HBMN:SW) Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.[1]
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.[2]
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies"[3] In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch.[4] HBM is based in Zug and managed by HBM Partners.[5] HBM acquired rival Swiss VC International BM Biomedicine in 2005.[6] The firm went public on the SIX Swiss exchange in 2008.[7][8][9]
HBM invests primarily in U.S., European, Chinese[10] and (on a smaller scale) Indian[11] firms and reported a net asset value of just over 1.7 billion Swiss Francs (approximately 1.9 billion U.S. dollars) at end of March 2024[12] It is often compared by economic-themed media to fellow Swiss healthcare investment firm BB Biotech.[13]
Though headquartered in Zug, the firm also has senior investment analysts and other staff based in New York and Hong Kong.[12]
References
[edit]- ^ "Aktie der Woche: HBM Healthcare". capital.de (in German). 2018-05-14. Retrieved 2024-01-24.
- ^ Gilb, Christopher (2022-07-22). "Ein gebürtiger Luzerner finanziert die Medikamente der Zukunft". Luzerner Zeitung (in German). Retrieved 2024-01-24.
- ^ "Seine Beteiligungsgesellschaft ist hochrentabel: Henri B. Meiers Geldmaschine heisst HBM". Handelszeitung (in Swiss High German). Retrieved 2024-01-24.
- ^ "Wenn Henri B. Meier ruft kommen 500 Mio. Fr". Finanz und Wirtschaft (in German). 2001-07-04. Retrieved 2024-01-24.
- ^ Brandenberg, Livio (2019-08-17). "Bald 2 Milliarden Wagniskapital in der Schweiz?". Luzerner Zeitung (in German). Retrieved 2024-01-24.
- ^ Staff, P. E. I. (2012-12-30). "HBM bids for rival Swiss life science VC". Private Equity International. Retrieved 2024-01-24.
- ^ "HBM Bioventures wagt endlich den Börsengang". Neue Zürcher Zeitung. 15 January 2008. Retrieved 24 January 2024.
- ^ "HBM Bioventures wants up to 150 mln Sfr from IPO". Reuters. 28 January 2008. Retrieved 24 January 2024.
- ^ Dealbook (2008-01-16). "Swiss Venture Capital Firm Eyes I.P.O." DealBook. Retrieved 2024-01-24.
- ^ "Sequoia China leads $150m series B round for Chinese biotech firm Visen". www.techinasia.com. Retrieved 2024-01-25.
- ^ Konde, Viren (2008-12-02). "Biotechnology business models: An Indian perspective". Journal of Commercial Biotechnology. 15 (3). doi:10.5912/jcb290. ISSN 1478-565X.
- ^ a b "HBM Healthcare Investments – Unique Investments in Private and Listed Life Sciences Companies" (PDF). HBM Healthcare Investments. March 2024. Retrieved July 11, 2024.
- ^ "BB Biotech und HBM – Wer im Biotech-Kasino die Nase vorn hat". Finanz und Wirtschaft (in German). 2023-04-18. Retrieved 2024-01-24.